Day: December 3, 2019

Coconut Creek, FL, Dec. 03, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Omni Medical Services (Omni) and NutraLife BioSciences Inc. (NutraLife) (OTCQB: NLBS) announce NutraLife to manufacture and provide finished CBD products for Omni’s new line of Omni CBD Solutions.Omni is a Michigan based physician-owned PLLC with eight years’ experience in providing medical cannabis evaluations to over 30,000 patients and currently has clinic locations in five states including Michigan, Ohio, Illinois, Oklahoma and Florida.  Omni plans to sell its CBD products at its clinic locations and by direct marketing to its patients. Omni’s CBD products will be available on its website http://omnidoctors.com/Omni’s CEO David Koyle states, “With our extensive experience in patient care, we’ve decided to produce a new line of products that we feel...

Las Vegas, NV, Dec. 03, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Hemp, Inc. (OTC PINK: HEMP) a global leader in the industrial hemp industry with bi-coastal processing centers, including the largest multipurpose industrial hemp processing facility in the western hemisphere, announced today news coverage in the nationally syndicated outlet, Sinclair Broadcast Group, a leading broadcast television company.The published article features commentary from Hemp, Inc. CEO, Bruce Perlowin, regarding the uncertainty of the cannabis industry with a federal ban on the product and massive costs that many investors did not anticipate. The article explains financial and regulatory hurdles that companies face such as hefty license costs and inaccessibility to banking.  Notably, Hemp, Inc. continues to position itself on the forefront of...

SAINT-MICHEL-DES-SAINTS, Québec, Dec. 03, 2019 (GLOBE NEWSWIRE) — Nouveau Monde Graphite Inc. (“Nouveau Monde” or “NMG”) (TSXV: NOU; OTCQX: NMGRF; Frankfurt: NM9) announces that Christina Lalli, Director of Investor Relations, will present live at VirtualInvestorConferences.com on December 4th.DATE: Wednesday, December 4, 2019TIME: 2:00pm ESTLINK: https://tinyurl.com/120519VICThis will be a live, interactive online event where investors are invited to ask the Company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.About Nouveau Monde GraphiteIn 2015, Nouveau Monde Graphite discovered a major and high-quality graphite deposit on its Matawinie property, located in Saint-Michel-des-Saints, 150 km north of Montréal....

MIAMI BEACH, Fla., Dec. 03, 2019 (GLOBE NEWSWIRE) — The Herzfeld Caribbean Basin Fund, Inc. (NASDAQ: CUBA) (the “Fund”) today announced its quarterly distribution pursuant to the Fund’s managed distribution policy (the “MDP”) and reported the results of its 2019 Annual Meeting of Stockholders.Quarterly DistributionThe Fund today declared the following distribution pursuant to the MDP:The primary purpose of the MDP is to provide stockholders with a constant, but not guaranteed, fixed minimum rate of distribution each quarter (currently set at the annual rate of 15% of the Fund’s net asset value (“NAV”) as determined on June 30, 2019 and payable in quarterly installments). The Fund cannot predict what effect, if any, the MDP will have on the market price of its shares or whether such market price will reflect a greater or lesser discount...

BLUE SOLUTIONSRaison sociale de l’émetteur :Blue SolutionsSociété AnonymeCapital : 145 815 330 EurosSiège social : Odet – 29500 Ergué-Gabéric421 090 051 R.C.S. QuimperDECLARATION AU TITRE DE L’ARTICLE  223-16 DU REGLEMENT GENERAL DE L’AUTORITE DES MARCHES FINANCIERSLa société informe ses actionnaires des éléments suivants au 30 novembre 2019 :Le 3 décembre 2019Il est précisé que par l’effet de la loi n°2014-384 dite « loi Florange » et sans qu’il n’ait été procédé à la modification matérielle des statuts, un droit de vote double est conféré aux actions entièrement libérées et pour lesquelles il est justifié d’une inscription nominative depuis deux ans au nom du même actionnaire.BOLLORECorrespondance à adresser : Tour Bolloré – 31-32, quai de Dion Bouton – F 92811 Puteaux cedex Tél. : 01 46 96 44 33 – Fax : 01 46 96 44 22 – Internet :...

AI-Powered Bank Dispute Platform Has Made Finscend One of American Banker’s “Six Standout Fintechs” AUSTIN, TX, Dec. 03, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Bravatek Solutions, Inc. (OTC Pink: BVTK), a provider of software, hardware and services to clients spanning a range of industries, has announced that it has entered into a strategic alliance agreement with Finscend, a fintech firm whose unique solution for streamlining credit and debit card dispute processing has drawn worldwide interest among banks and card issuers.Before designing its solution, Finscend first spent three years studying over 2,000 card disputes submitted to hundreds of card issuers worldwide and the chargebacks that they did, and did not, approve. The result was its Bank Dispute Platform™ (BDP), which modernizes what has been, until now, a primarily...

Útgerðarfélag Reykjavíkur hefur óskað eftir að meðfylgjandi tillaga verði sett á dagskrá á hluthafafundi Brims þann 12. desember 2019.ViðhengiTillaga Útgerðarfélags Reykjavíkur

NEWPORT BEACH, Calif. and SALT LAKE CITY, Dec. 03, 2019 (GLOBE NEWSWIRE) — VERB Technology Company, Inc. (NASDAQ: VERB) (“VERB” or the “Company”), a leader in business-focused interactive video CRM, marketing, and sales enablement applications, announced Kyäni, an internationally recognized health and wellness brand has signed-on to adopt VERB’s interactive video CRM platform, including VERB’s LEARN application, for a global launch in almost 30 of Kyäni’s markets in multiple languages. Kyäni also plans to utilize VERB’s sampling program and back-office reporting tools.Kyäni offers a variety of health and wellness focused products, ranging from skin care solutions to protein powders. Through the use of VERB’s LEARN app, Kyäni customers can better educate themselves on the health benefits and applications of...

Cranbury, NJ, Dec. 03, 2019 (GLOBE NEWSWIRE) — Rafael Pharmaceuticals Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that Ariela Noy, M.D., hematologic oncologist at Memorial Sloan Kettering Cancer Center and principal investigator on a Phase 2 clinical trial of CPI-613® (devimistat) for patients with relapsed or refractory Burkitt lymphoma/leukemia or high-grade B-Cell lymphoma, will lead a poster presentation at the 61st Annual American Society of Hematology (ASH) Meeting and Exposition. Dr. Noy will discuss how devimistat works in patients with Burkitt lymphoma, designed to cause cancer cell death by disrupting the enzyme activity of cancer cells. She will address the currently dismal prognosis for relapsed Burkitt lymphoma, as well as the study design...